Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Use and effectiveness of zoledronic acid as a second-line treatment for osteoporosis

FY 2020-21

Summary
Osteoporosis is a brittle bone disease that can result in debilitating fractures. Osteoporosis is a major health problem in Canada with over 2 million people affected, an estimated 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture. The spine and hip are common fracture sites in older adults. Spine fractures reduce quality of life and are often accompanied by difficulty breathing. Hip fractures are deadly: up to one third of patients die within the year after hip fracture. In addition, up to a quarter of patients enter a nursing home for the first time following hip fracture. Thankfully, medications are available to strengthen bones and reduce fracture risk. In Ontario, residents over the age of 65 receive drug coverage through the Ontario Drug Benefit program. Weekly doses of oral bisphosphonates are the first-choice therapy, which are taken by mouth and can be hard on the stomach. However, some patients stop taking their medications because they are not working, are difficult to swallow and then cause digestive issues. As a result, patients need to switch to more potent therapy, such as an annual infusion of zoledronic acid. Zoledronic acid is very effective in preventing fractures and recently, questions about how often patients need an infusion of zoledronic acid and when it is appropriate to stop therapy have arisen. Uncertainty about the relationship between dosing frequency and the benefits and harms of zoledronic acid are important clinical questions identified by Osteoporosis Canada. We are working directly with Osteoporosis Canada to answer questions about zoledronic acid therapy for osteoporosis. Results will inform clinical practice guidelines currently in development.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
439381
Name
Konstantelos Natalia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
Use and effectiveness of zoledronic acid as a second-line treatment for osteoporosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Drug Safety; Drug Utilization; Gender And Health; Health Services Research; Musculoskeletal Health; Osteoporosis; Pharmacoepidemiology
Abstract
Osteoporosis is a brittle bone disease that can result in debilitating fractures. Osteoporosis is a major health problem in Canada with over 2 million people affected, an estimated 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture. The spine and hip are common fracture sites in older adults. Spine fractures reduce quality of life and are often accompanied by difficulty breathing. Hip fractures are deadly: up to one third of patients die within the year after hip fracture. In addition, up to a quarter of patients enter a nursing home for the first time following hip fracture. Thankfully, medications are available to strengthen bones and reduce fracture risk. In Ontario, residents over the age of 65 receive drug coverage through the Ontario Drug Benefit program. Weekly doses of oral bisphosphonates are the first-choice therapy, which are taken by mouth and can be hard on the stomach. However, some patients stop taking their medications because they are not working, are difficult to swallow and then cause digestive issues. As a result, patients need to switch to more potent therapy, such as an annual infusion of zoledronic acid. Zoledronic acid is very effective in preventing fractures and recently, questions about how often patients need an infusion of zoledronic acid and when it is appropriate to stop therapy have arisen. Uncertainty about the relationship between dosing frequency and the benefits and harms of zoledronic acid are important clinical questions identified by Osteoporosis Canada. We are working directly with Osteoporosis Canada to answer questions about zoledronic acid therapy for osteoporosis. Results will inform clinical practice guidelines currently in development.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Konstantelos, Natalia
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~